| Literature DB >> 33427749 |
Hassen Kared1, Andrew D Redd2,3, Evan M Bloch4, Tania S Bonny4, Hermi Sumatoh1, Faris Kairi1, Daniel Carbajo1, Brian Abel1, Evan W Newell1,5, Maria P Bettinotti4, Sarah E Benner4, Eshan U Patel4,6, Kirsten Littlefield7, Oliver Laeyendecker2,3, Shmuel Shoham3, David Sullivan7, Arturo Casadevall7, Andrew Pekosz7, Alessandra Nardin1, Michael Fehlings1, Aaron Ar Tobian4, Thomas C Quinn2,3.
Abstract
Characterization of the T cell response in individuals who recover from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its contribution to protective immunity. A multiplexed peptide-MHC tetramer approach was used to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition in a cross-sectional sample of 30 coronavirus disease 2019 convalescent individuals. T cells were evaluated using a 28-marker phenotypic panel, and findings were modelled against time from diagnosis and from humoral and inflammatory responses. There were 132 SARS-CoV-2-specific CD8+ T cell responses detected across 6 different HLAs, corresponding to 52 unique epitope reactivities. CD8+ T cell responses were detected in almost all convalescent individuals and were directed against several structural and nonstructural target epitopes from the entire SARS-CoV-2 proteome. A unique phenotype for SARS-CoV-2-specific T cells was observed that was distinct from other common virus-specific T cells detected in the same cross-sectional sample and characterized by early differentiation kinetics. Modelling demonstrated a coordinated and dynamic immune response characterized by a decrease in inflammation, increase in neutralizing antibody titer, and differentiation of a specific CD8+ T cell response. Overall, T cells exhibited distinct differentiation into stem cell and transitional memory states (subsets), which may be key to developing durable protection.Entities:
Keywords: COVID-19; Cellular immune response; Immunology; MHC class 1; T cells
Mesh:
Substances:
Year: 2021 PMID: 33427749 PMCID: PMC7919723 DOI: 10.1172/JCI145476
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808